The Latest Cardiac and Vascular News
Merger unites three companies created by life sciences venture capital firm ATP—Gala Therapeutics, Galaxy Medical, and Galvanize Therapeutics—to create a single company based on the AliyaTM Pulsed Electric Field (PEF) energy platform Galvanize is developing and commercializing systems for chronic bronchitis symptoms, cardiac arrhythmias, solid tumors, and drug delivery $100 million funding […]
MALVERN, Pa., Sept. 15, 2022 /PRNewswire/ — Excision Medical, Inc., a privately held medical device company addressing the rapidly growing need for lifetime management of aortic stenosis through leaflet modification technology, announced today that it has raised a $2.5M financing led by the internal team, and added Drs. James McCabe, MD (UW Medicine, Seattle, WA) and Adam […]
The $42 million USD expansion demonstrates the company’s continued investment to support its global customers which include hospitals and healthcare providers conducting cardiovascular surgery. Terumo Cardiovascular is one of the world’s leading providers of perfusion products. The Costa Rica facility will produce the Company’s complete line of custom perfusion circuits (tubing kits) which are […]
Prominent France based interventional radiologist to leverage his expertise to assist the Company to achieve its future objective for the LIBERTY® Robotic System HINGHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), which continues to build a network of global leaders in the endovascular interventional space […]
TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation Paris, France and Munich, Germany, September 15, 2022 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today that it has successfully raised €47m from the […]
A cash position of €15.4 million at June 30, 2022. Financial visibility until the last quarter of 2023, excluding potential additional revenues. Continued execution of the strategic and operational roadmap for future commercialization. LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL / PEA/SME eligible) (Paris:ALVAL), a Research and Development […]
All Merger-related proposals approved at the Annual Meeting of Stockholders BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders […]
Leadership Team Continues to Expand with Addition of Key Leader in Clinical Operations “Julie brings nearly two decades of clinical development operations experience to DiaMedica across a wide breadth of pharmaceutical therapeutic areas, including Phase 3 pivotal programs. She is an expert in trial execution and management of the myriad […]
MIAMI, Sept. 13, 2022 /PRNewswire/ — RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced that it has raised an additional $10.5 million, bringing its cumulative financing to over $25 million. The financing was led by Syntheon and Santé Ventures who were joined by Epidarex Capital, Hatteras Venture Partners, and Broadview Ventures. RapidPulse plans […]
VILLANOVA, Pa., Sept. 13, 2022 /PRNewswire/ — Prolifagen Therapeutics, a biotech startup developing medicines for cardiac regeneration, has appointed M. Alexander Shaw, PhD, as Chief Executive Officer. In this role, Dr. Shaw will lead Prolifagen’s efforts in bringing new medicines to market to prevent development of heart failure in patients with large myocardial […]
